Bill Text: NY A08268 | 2019-2020 | General Assembly | Introduced
Bill Title: Relates to mandating insurance coverage for medical devices and products to treat withdrawal symptoms which are approved by the food and drug administration.
Spectrum: Partisan Bill (Democrat 1-0)
Status: (Introduced - Dead) 2020-01-08 - referred to insurance [A08268 Detail]
Download: New_York-2019-A08268-Introduced.html
STATE OF NEW YORK ________________________________________________________________________ 8268 2019-2020 Regular Sessions IN ASSEMBLY June 11, 2019 ___________ Introduced by M. of A. L. ROSENTHAL -- read once and referred to the Committee on Insurance AN ACT to amend the insurance law, in relation to mandating insurance coverage for medical devices to treat withdrawal symptoms The People of the State of New York, represented in Senate and Assem- bly, do enact as follows: 1 Section 1. Subparagraph (A) of paragraph 30 of subsection (i) of 2 section 3216 of the insurance law, as amended by section 5 of subpart A 3 of part BB of chapter 57 of the laws of 2019, is amended to read as 4 follows: 5 (A) Every policy that provides hospital, major medical or similar 6 comprehensive coverage shall provide inpatient coverage for the diagno- 7 sis and treatment of substance use disorder, including detoxification 8 and rehabilitation services, including the use of medications, medical 9 devices and products approved and/or cleared by the food and drug admin- 10 istration for the treatment of withdrawal symptoms. Such inpatient 11 coverage shall include unlimited medically necessary treatment for 12 substance use disorder treatment services provided in residential 13 settings. Further, such inpatient coverage shall not apply financial 14 requirements or treatment limitations, including utilization review 15 requirements, to inpatient substance use disorder benefits that are more 16 restrictive than the predominant financial requirements and treatment 17 limitations applied to substantially all medical and surgical benefits 18 covered by the policy. 19 § 2. Paragraph 30 of subsection (i) of section 3216 of the insurance 20 law, as amended by section 7 of subpart B of part J of chapter 57 of the 21 laws of 2019, is renumbered paragraph 30-a. 22 § 3. Paragraph 7-a of subsection (l) of section 3221 of the insurance 23 law, as added by section 2 of part B of chapter 69 of the laws of 2016, 24 is amended to read as follows: EXPLANATION--Matter in italics (underscored) is new; matter in brackets [] is old law to be omitted. LBD06895-06-9A. 8268 2 1 (7-a) Every policy that provides medical, major medical or similar 2 comprehensive-type large group coverage shall provide coverage for medi- 3 cation for the detoxification or maintenance treatment, including 4 medical devices or products for the treatment of withdrawal symptoms, of 5 a substance use disorder approved by the food and drug administration 6 for the detoxification or maintenance treatment of substance use disor- 7 der. 8 § 4. Subsection (l-1) of section 4303 of the insurance law, as added 9 by section 3 of part B of chapter 69 of the laws of 2016, is amended to 10 read as follows: 11 (l-1) Every contract that provides medical, major medical, or similar 12 comprehensive-type large group coverage shall provide coverage for medi- 13 cation for the detoxification or maintenance treatment, including 14 medical devices or products for the treatment of withdrawal symptoms, of 15 a substance use disorder approved by the food and drug administration 16 for the detoxification or maintenance treatment of substance use disor- 17 der. 18 § 5. Subparagraph (A) of paragraph 31 of subsection (i) of section 19 3216 of the insurance law, as amended by section 6 of subpart A of part 20 BB of chapter 57 of the laws of 2019, is amended to read as follows: 21 (A) Every policy that provides medical, major medical or similar 22 comprehensive-type coverage shall provide outpatient coverage for the 23 diagnosis and treatment of substance use disorder, including detoxifica- 24 tion and rehabilitation services, including the use of medications, 25 medical devices and products approved and/or cleared by the food and 26 drug administration for the treatment of withdrawal symptoms. Such 27 coverage shall not apply financial requirements or treatment limitations 28 to outpatient substance use disorder benefits that are more restrictive 29 than the predominant financial requirements and treatment limitations 30 applied to substantially all medical and surgical benefits covered by 31 the policy. 32 § 6. This act shall take effect on the same date and in the same 33 manner as subpart A of part BB of chapter 57 of the laws of 2019, takes 34 effect and shall apply to policies and contracts issued, renewed, modi- 35 fied, altered or amended on and after such date; provided, however, that 36 section two of this act shall take effect on the same date and in the 37 same manner as section 7 of subpart B of part J of chapter 57 of the 38 laws of 2019, takes effect.
